E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic anal fissure |
Fisura anal crónica |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess whether the technique of ultrasound-guided botulinum toxin infiltration is more effective and safer than the standard one, by controlling the infiltration sites. The aim is to analyze whether the location of the botulinum toxin infiltration is an important factor in the result of the treatment. On the other hand, the aim is to standardize a technique and make it much more precise for the localization of the infiltration, through the use of the endorectal ultrasound probe. Therefore, our objective is to establish a novel technique that complements the standard technique, is reproducible and does not increase the risks and is even safer, as it controls the site of toxin infiltration. |
Valorar si la técnica de infiltración de toxina botulínica ecoguiada es más efectiva, y segura que la estándar, al controlar los puntos de infiltración. Se trata de analizar si la localización de la infiltración de la toxina botulínica es un factor importante en el resultado del tratamiento. porcentaje de valorar si el Por otro lado, se busca estandarizar una técnica y hacerla mucho más precisa para la localización de la infiltración, mediante el uso de la sonda ecográfica endorrectal. Por tanto, nuestro objetivo es instaurar una técnica novedosa que complementa a la técnica estándar, reproducible y que no incrementa los riesgos siendo incluso más segura, al controlar el lugar de la infiltración de la toxina |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All patients of legal age who sign the informed consent form and are diagnosed with chronic anal fissure will be included in the study. Chronic anal fissure will be considered as that which has been evolving for more than 6 weeks, in spite of various hygienic-dietary treatments and/or relaxants (NTG) or calcium blockers and which macroscopically presents some of the aspects of chronicity referred to: indurated edges, observation in the fundus of internal anal sphincter fibers and/or sentinel polyp persisting for more than 6 weeks. |
Se incluirán en el estudio todos aquellos pacientes mayores de edad, que firmen el consentimiento informado y estén diagnosticados de fisura anal crónica. Se considerará fisura anal crónica a aquella que lleva más de 6 semanas de evolución, a pesar de diversos tratamientos higiénico-dietéticos y/o relajantes (NTG) o bloqueadores del calcio y que macroscópicamente presenta alguno de los aspectos de cronicidad referidos: bordes indurados, observación en el fondo de fibras de EAI y /o pólipo centinela que persista más de 6 semanas. |
|
E.4 | Principal exclusion criteria |
Patients in whom botulinum toxin injection is contraindicated are excluded from the study: patients with alterations of neuromuscular transmission such as myasthenia gravis, Lambert Eaton myasthenic syndrome, inflammatory bowel disease, concomitant treatment with aminoglycosides, pregnancy or lactation, asthma or adverse reactions to treatment. |
Estarán excluidos del estudio los pacientes en que está contraindicada la inyección de toxina botulínica: pacientes con alteraciones de la transmisión neuromusculares como miastenia gravis, síndrome miasténico Lambert Eaton, Enfermedad Inflamatoria intestinal. tratamiento concomitante con aminoglucósidos, embarazo o lactancia, asma o reacciones adversas al tratamiento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main variables that we will specify in the study will be whether there is healing of the fissure (epithelialization of the fissure and disappearance of symptoms such as pain or bleeding), that there is no recurrence and, finally, to assess the complications of treatment (mainly anal incontinence), especially anal incontinence. |
Las principales variables que precisaremos en el estudio serán, si existe curación de la fisura, (epitelización de la misma y desaparición de la sintomatología como el dolor o el sangrado), que no haya recidiva y, por último, valorar las complicaciones del tratamiento (fundamentalmente la incontinencia anal) sobre todo la incontinencia anal. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
2, 8 and 24 weeks |
2, 8 y 24 semanas |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last follow-up visit of the last included patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |